Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Waks on Unmet Needs in Patients With HER2+ Breast Cancer

June 26th 2024

Adrienne G. Waks, MD, discusses efforts to address unmet needs in HER2-positive breast cancer.

Dr Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer

June 26th 2024

David Rimm, MD, PhD, discusses challenges in distinguishing between HER2-low and HER2-ultralow breast cancer using current diagnostic kits.

Intrathecal Dendritic Cells Under Evaluation for Leptomeningeal Disease in TNBC and HER2+ Breast Cancer

June 26th 2024

Peter Forsyth, MD, on the investigation of intrathecal dendritic cells for leptomeningeal disease in triple-negative and HER2-positive breast cancer.

Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer

June 26th 2024

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PIK3CA alterations, AKT1 alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.

First-Line Treatment Options in HR+/HER2- Locally Advanced and Metastatic Breast Cancer and Challenges with Treatment Resistance

June 26th 2024

Medical experts share their strategies for choosing initial treatment options for HR+/HER2- locally advanced or metastatic breast cancer, debating the most effective frontline therapies based on clinical trial evidence, while also discussing their aspirations for a new standard of care, and the challenges of managing disease progression.

Trastuzumab Deruxtecan (T-DXd) vs Physician’s Choice of Chemotherapy (TPC) in Patients (pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy (ET): Primary Results From DESTINY-Breast06 (DB-06)

June 25th 2024

Dr. Aditya Bardia presents the findings of DESTINY-Breast06 (NCT04494425) in chemotherapy naive patients with HER2-low and HER2-ultra low metastatic breast cancer demonstrating progression-free survival of trastuzumab deruxtecan compared to chemotherapy treatment of physician’s choice.

First-Line Toripalimab Plus Chemo Wins Approval in China for Advanced TNBC

June 25th 2024

China’s NMPA approved toripalimab plus nab-paclitaxel for the first-line treatment of recurrent or metastatic triple-negative breast cancer.

Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

June 25th 2024

Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.

Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

June 25th 2024

Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.

Evolution of Testing Strategies for ESR1

June 25th 2024

The key opinion leaders (KOLs) review the current testing methods for detecting ESR1 mutations and explore the existing strategies employed to overcome or delay the development of these mutations and the associated endocrine resistance in patients with HR+/HER2- metastatic breast cancer.

Prevalence and Testing Strategies for ESR1

June 25th 2024

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the clinical significance of *ESR1* mutations in HR+/HER2- metastatic breast cancer patients, including their impact on disease prognosis, treatment outcomes, and the increasing prevalence of these mutations with each line of endocrine therapy, ultimately informing their therapeutic approach.

Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

June 24th 2024

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.

Challenges in Diagnosing HER2+ Breast Cancer

June 24th 2024

A panel of experts on breast cancer provide insights on challenges encountered during the diagnosis of HER2+ early breast cancer and discuss the role of immunohistochemistry and FISH testing.

Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions

June 24th 2024

Key opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.

Trilaciclib Before Gemcitabine/Carboplatin Misses OS End Point in Metastatic TNBC

June 24th 2024

Trilaciclib plus chemotherapy failed to improve overall survival in metastatic triple-negative breast cancer.

Patient Selection Takes Priority as Standard of Cares Shift in HR+ and HER2+ Breast Cancer

June 23rd 2024

Lauren E. Nye, MD, discusses the use of CDK4/6 inhibitors in HR-positive metastatic breast cancer and the evolution of ADCs in HER2-positive disease.

European Commission Approves Capivasertib Plus Fulvestrant for ER+ Breast Cancer

June 20th 2024

Capivasertib/fulvestrant was approved in the EU for pretreated, ER-positive, HER2‑negative advanced cancer with 1 or more PIK3CA, AKT1, or PTEN alterations.

The Pursuit of Targeted Agents Broadens the HR+ Breast Cancer Treatment Paradigm

June 19th 2024

Lauren E. Nye, MD, highlights reasons to look beyond CDK4/6 inhibitors when determining treatments for patients with hormone receptor–positive advanced breast cancer and more.

Dr Lobbous on Tucatinib Plus Trastuzumab/Capecitabine in HER2+ Breast Cancer Leptomeningeal Metastases

June 19th 2024

Mina Lobbous, MD, MPH, on tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases from HER2-positive breast cancer.

Dr Forsyth on Leptomeningeal Disease in HER2+ Breast Cancer and TNBC

June 18th 2024

Peter Forsyth, MD, discusses the importance of evaluating leptomeningeal disease caused by TNBC and HER2+ breast cancer.